A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)

被引：2
|
作者：
Socinski, M. [1 ]
Gil, M. [2 ]
Shahidi, J. [3 ]
Chao, G. Y. [4 ]
Villaruz, L. [1 ]
机构：
[1] Univ Pittsburgh, Med Oncol, UPMC Canc Pavil, Pittsburgh, PA USA
[2] Eli Lilly Polska, Oncol, Warsaw, Poland
[3] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Biostat, Indianapolis, IN 46285 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.98
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1298TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Wang, Rui-Rui
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 367 - 367
  • [42] Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results
    Gentzler, R. D.
    Mohindra, N. A.
    Hanna, N.
    Chae, Y. K.
    Jalal, S. I.
    Hall, R.
    Villaflor, V. M.
    Reckamp, K. L.
    Koczywas, M.
    Sullivan, D.
    Wood, L.
    Patel, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 236 - 236
  • [43] Biomarker Analysis of Camrelizumab Plus Nab-paclitaxel and Carboplatin as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer
    Yu, J.
    Zhou, C.
    Wang, L.
    Jiang, T.
    Xiong, A.
    Yuan, J.
    Shi, W.
    Ren, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S209 - S210
  • [44] Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
    Tabah, Ashley
    Huggar, David
    Kish, Jonathan
    Bapat, Bela
    Liassou, Djibril
    Gajra, Ajeet
    Miller, Talia
    Copher, Ronda
    Patel, Manali, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] UTILIZATION AND COST OF SUPPORTIVE CARE AMONG PATIENTS RECEIVING NAB-PACLITAXEL plus CARBOPLATIN VERSUS SB-PACLITAXEL plus CARBOPLATIN AS FIRST-LINE TREATMENT FOR METASTATIC NON-SMALL CELL LUNG CANCER
    Patel, M.
    Ni, Q.
    VALUE IN HEALTH, 2016, 19 (03) : A155 - A155
  • [46] Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
    Shui, Lin
    Cheng, Ke
    Li, Xiaofen
    Shui, Pixian
    Zhou, Xiaohan
    Li, Jian
    Yi, Cheng
    Cao, Dan
    BMC CANCER, 2020, 20 (01)
  • [47] Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
    Lin Shui
    Ke Cheng
    Xiaofen Li
    Pixian Shui
    Xiaohan Zhou
    Jian Li
    Cheng Yi
    Dan Cao
    BMC Cancer, 20
  • [48] A phase II, open-label, single-arm study of QL1604 plus paclitaxel-cisplatin/carboplatin as first-line treatment in patients with recurrent or metastatic cervical cancer
    Liu, J.
    Fang, C.
    Zhou, Q.
    He, L.
    Yu, J.
    Li, Y.
    Feng, M.
    Pan, M.
    Zhao, L.
    Tang, D.
    Li, X.
    Tan, B.
    An, R.
    Zheng, X.
    Si, M.
    Zhang, B.
    Li, L.
    Kang, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1506 - S1506
  • [49] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
    Motohiro Tamiya
    Akihiro Tamiya
    Hidekazu Suzuki
    Yoshihiko Taniguchi
    Kanako Katayama
    Shojiro Minomo
    Keiko Nakao
    Naoko Takeuchi
    Yoshinobu Matsuda
    Yujiro Naito
    Takayuki Shiroyama
    Norio Okamoto
    Kyoichi Okishio
    Toru Kumagai
    Shinji Atagi
    Fumio Imamura
    Tomonori Hirashima
    Investigational New Drugs, 2021, 39 : 1106 - 1112
  • [50] Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer
    Okamoto, Isamu
    Yamamoto, Nobuyuki
    Kubota, Kaoru
    Ohe, Yuichiro
    Nogami, Naoyuki
    Murakami, Haruyasu
    Yamaya, Hidetoshi
    Ono, Katsuhiro
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1132 - 1137
12345